Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma

Wei Xu(Jiangsu Province Hospital), Huayuan Zhu(Jiangsu Province Hospital), Ruize Chen(Jiangsu Province Hospital), Jianyong Li(Jiangsu Province Hospital), Hua Yin(Jiangsu Province Hospital), Jia‐Zhu Wu(Augusta University Health), Yi Xia(The University of Texas MD Anderson Cancer Center), Jin‐Hua Liang(Broad Institute), Lei Fan(Jiangsu Province Hospital), Li Wang(University of Science and Technology of China)
Leukemia Research
April 30, 2021
10.1016/j.leukres.2021.106607
Cited by 7

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|238
Circular RNA circRNA_15698 aggravates the extracellular matrix of diabetic nephropathy mesangial cells via miR‐185/TGF‐β1
|Journal of Cellular Physiology|2018|172